Showing papers by "Barbara Fisher published in 2017"
University of Colorado Denver1, Washington University in St. Louis2, Baptist Hospital of Miami3, Summa Akron City Hospital4, University of Rochester Medical Center5, University of Western Ontario6, University of California, San Francisco7, Memorial Sloan Kettering Cancer Center8, Vanderbilt University Medical Center9
TL;DR: Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlate with radiation dose to the small bowel and APC, and associations will be incorporated in the dose-volume normal tissue constraint design for future NRG oncology anal cancer studies.
Abstract: Purpose NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). Methods and Materials NRG Oncology RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel, loosely contoured anterior pelvic contents (APC), and uninvolved colon outside the target volume (UC). Univariate logistic regression was performed to evaluate association between volumes of each structure receiving doses ≥5 to 60 Gy (V5-V60) in 5-Gy increments between patients with and without grade ≥2 acute and late GI AEs, and grade ≥3 acute GI AEs. Additional patient and treatment factors were evaluated in multivariate logistic regression (acute AEs) or Cox proportional hazards models (late AEs). Results Among 52 evaluable patients, grade ≥2 acute, grade ≥2 late, and grade ≥3 acute GI AEs were observed in 35, 17, and 10 patients, respectively. Trends (P 4 cm, and worse Zubrod performance status. Small bowel volumes of 186.0 cc, 155.0 cc, 41.0 cc, and 30.4 cc receiving doses greater than 25, 30, 35, and 40 Gy, respectively, correlated with increased risk of acute grade ≥2 GI AEs. Conclusions Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlate with radiation dose to the small bowel and APC. Such associations will be incorporated in the dose-volume normal tissue constraint design for future NRG oncology anal cancer studies.
37 citations
13 citations
Rhode Island Hospital1, Rush University Medical Center2, University of Maryland, Baltimore3, University of Colorado Denver4, Thomas Jefferson University5, University of Texas MD Anderson Cancer Center6, University of California, San Diego7, Memorial Sloan Kettering Cancer Center8, Kaiser Permanente9, Mayo Clinic10, University of Southern California11, University of Rochester Medical Center12
TL;DR: NRG/RTOG 0848 is a 2-step study designed to determine whether erlotinib added to gemcitabine (G) (randomized Ph II) &/or adjuvant radiation with concurrent 5-FU or capecitABine ...
Abstract: 4007Background: NRG/RTOG 0848 is a 2-step study designed to determine whether erlotinib (E) added to gemcitabine (G) (randomized Ph II) &/or adjuvant radiation with concurrent 5-FU or capecitabine ...
12 citations
Barrow Neurological Institute1, Cleveland Clinic2, University of California, San Francisco3, University of Oklahoma Health Sciences Center4, Mount Sinai St. Luke's and Mount Sinai Roosevelt5, University of Maryland, Baltimore6, Washington University in St. Louis7, Emory University8, University of Western Ontario9, McGill University Health Centre10, Hamilton Health Sciences11, University of Texas MD Anderson Cancer Center12
7 citations